2-(Phenylazo)pyridineplatinum(II) Catecholates Showing Photocytotoxicity, Nuclear Uptake, and Glutathione-Triggered Ligand Release
- 12 December 2014
- journal article
- research article
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 54 (1) , 253-264
Abstract
Platinum(II) complexes [Pt(pap)(an-cat)] (1) and [Pt(pap)(py-cat)] (2) with 2-(phenylazo)pyridine (pap), 4-[2-[(anthracen-9-ylmethylene)amino]ethyl]benzene-1,2-diol (H2an-cat), and 4-[2-[(pyren-1-ylmethylene)amino]ethyl]benzene-1,2-diol (H2py-cat) were prepared, and their photoinduced cytotoxicity was studied. The complexes were found to release catecholate ligand in the presence of excess glutathione (GSH), resulting in cellular toxicity in the cancer cells. The catecholate complex [Pt(pap)(cat)] (3) was prepared and used as a control. Complex 3, which is structurally characterized by X-ray crystallography, has platinum(II) in a distorted square-planar geometry. The complexes are redox-active, showing responses near 0.6 and 1.0 V versus SCE in N,N-dimethylformamide/0.1 M tetrabutylammonium perchlorate corresponding to a two-step catechol oxidation process and at −0.3 and −1.3 V for reduction of the pap ligand. Complex 1 showed remarkable light-induced cytotoxicity in HaCaT (human skin keratinocytes) and MCF-7 (human breast cancer) cells, giving IC50 value of ∼5 μM in visible light of 400–700 nm and >40 μM in the dark. The 2′,7′-dichlorofluorescein diacetate (DCFDA) assay showed the generation of reactive oxygen species (ROS), which seems to trigger apoptosis, as is evident from the annexin V–fluorescein isothiocyanate (FITC)/propidium iodide (PI) assay. The fluorescence microscopic images showed significant nuclear localization of the complexes and free ligands. A mechanistic study revealed possible reduction of the coordinated azo bond of pap by cellular GSH, releasing the catecholate ligand and resulting in remarkable photochemotherapeutic action of the complexes.Keywords
Funding Information
- Council of Scientific and Industrial Research (CSIR/01(2559)/12/EMR-II/2012, SR/S5/MBD-02/2007)
- Department of Science and Technology, Ministry of Science and Technology
This publication has 56 references indexed in Scilit:
- Detouring of cisplatin to access mitochondrial genome for overcoming resistanceProceedings of the National Academy of Sciences, 2014
- Pros and cons of bifunctional platinum(iv) antitumor prodrugs: two are (not always) better than oneDalton Transactions, 2014
- Metallodrugs in Medicinal Inorganic ChemistryChemical Reviews, 2014
- Conjugation of vitamin E analog α-TOS to Pt(iv) complexes for dual-targeting anticancer therapyChemical Communications, 2013
- Monofunctional and Higher-Valent Platinum Anticancer AgentsInorganic Chemistry, 2013
- Targeting and delivery of platinum-based anticancer drugsChemical Society Reviews, 2012
- Enhancing Photodynamyc Therapy Efficacy by Combination Therapy: Dated, Current and Oncoming StrategiesCancers, 2011
- The status of platinum anticancer drugs in the clinic and in clinical trialsDalton Transactions, 2010
- Anticancer drug development: the grand challengesNature Reviews Drug Discovery, 2010
- Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetateProceedings of the National Academy of Sciences, 2009